Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373951 | 1.00 | LTA4H (0.56) | LTA4HS1PR1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL1372071 | 0.93 | S1PR1 (0.62) | LTA4HS1PR1 | |
| SCHEMBL1372073 | 0.93 | S1PR1 (0.62) | LTA4HS1PR1 | |
| SCHEMBL1373753 | 0.91 | LTA4H (0.56) | LTA4HS1PR1L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1373748 | 0.91 | LTA4H (0.56) | LTA4HS1PR1L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1371620 | 0.88 | S1PR1 (0.58) | LTA4HS1PR1ALDH1A1KMT2A | |
| SCHEMBL1371622 | 0.88 | S1PR1 (0.58) | LTA4HS1PR1ALDH1A1KMT2A | |
| SCHEMBL1372249 | 0.88 | S1PR1 (0.58) | LTA4HS1PR1 | |
| SCHEMBL1372246 | 0.88 | S1PR1 (0.58) | LTA4HS1PR1 | |
| SCHEMBL1372965 | 0.85 | LTA4H (0.75) | LTA4HRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | LTA4H 1113/4885S1PR1 1/4885L3MBTL1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.